Agios Pharmaceuticals | AGIO - Assets


Agios Pharmaceuticals reported $1.11B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 95.64B 3.14B Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Astellas Pharma JPY 3.69T 125.48B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bayer EUR 107.29B 659M Jun/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026